Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates
– Net product revenue of
– VYVGART® (efgartigimod alfa injection) sales of
– Expansion of Zai Lab’s global oncology pipeline with a next generation ROR1 antibody-drug conjugate (ADC) program
– Three product approvals in
– Strong balance sheet with a cash position1 of
– Company to host conference call and webcast on
“In the second quarter, we achieved impressive commercial growth, maintained financial discipline, and made significant strides across our product portfolio, highlighting our capability to execute on our strategic objectives,” said Dr.
“Our net product revenues grew 45% y-o-y in the second quarter, driven by the successful commercialization of VYVGART,” said
|
1 |
Cash position includes cash and cash equivalents, current restricted cash, and short-term investments. |
Second-Quarter 2024 Financial Results
- Product revenue, net was
$100.1 million in the second quarter of 2024, compared to$68.9 million for the same period in 2023, representing 45% y-o-y growth and 47% y-o-y growth at CER. This increase was primarily driven by increased sales for VYVGART since its launch inSeptember 2023 and China’s National Reimbursement Drug List (NRDL) listing inJanuary 2024 , and increased sales for ZEJULA and NUZYRA. Primary drivers of this revenue growth included the following:
- ZEJULA®:
$45.0 million in the second quarter of 2024, an increase of 5% y-o-y from$43.0 million for the same period in 2023, driven by increased hospital sales in first-line ovarian cancer and increased duration of treatment and supported by the renewal of ZEJULA’s NRDL listing for the maintenance treatment of adult patients with first-line and recurrent ovarian cancer, effectiveJanuary 1, 2024 .
- VYVGART®:
$23.2 million in the second quarter of 2024, compared to$0.1 million for the same period in 2023, driven by its NRDL listing for the treatment of generalized myasthenia gravis (gMG) effectiveJanuary 1, 2024 and positive physician and patient reception as well as increased patient access as VYVGART is added to hospital formularies. VYVGART was launched for the treatment of gMG inSeptember 2023 .
- NUZYRA®:
$12.3 million in the second quarter of 2024, an increase of 165% y-o-y compared to$4.6 million for the same period in 2023, driven by the NRDL listings for the IV formulation of NUZYRA for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in the first quarter of 2023 and the oral formulation for these indications in the first quarter of 2024.
- Research and Development (R&D) expenses were
$61.6 million in the second quarter of 2024, compared to$76.7 million for the same period in 2023. This decrease was primarily due to decreased milestone fees for our license and collaboration agreements, partially offset by increased clinical trial expenses related to newly initiated studies and progress of existing studies.
- Selling, General and Administrative expenses were
$79.7 million in the second quarter of 2024, compared to$67.9 million for the same period in 2023. This increase was primarily driven by higher general selling expenses and headcount growth primarily to support VYVGART.
- Net loss was
$80.3 million in the second quarter of 2024, or a loss per ordinary share attributable to common stockholders of$0.08 (or loss per American Deposit Share (ADS) of$0.82 ), compared to a net loss of$120.9 million for the same period in 2023, or a loss per ordinary share of$0.13 (or loss per ADS of$1.25 ).
- Cash and cash equivalents, short-term investments, and current restricted cash totaled
$730.0 million as ofJune 30, 2024 , compared to$750.8 million as ofMarch 31, 2024 .
Corporate Updates
Below are key corporate updates since our last earnings release:
- Business Development: In
July 2024 ,Zai Lab entered into a strategic partnership and global license agreement with MabCare Therapeutics. Through this collaboration, the Company expanded its global oncology pipeline with a next generation ADC targeting ROR1, ZL-6301. ZL-6301 has the potential to be used in the treatment of solid tumors where ROR1 is commonly expressed and in hematological malignancies where ROR1 is a validated target. ZL-6301 has demonstrated an encouraging pre-clinical profile, and it is currently in the IND-enabling stage.Zai Lab plans to focus on advancing its global development.
- Organizational Update: In
June 2024 ,Zai Lab appointed Dr.Rafael Amado as President, Head ofGlobal Research and Development, expanding his role to encompass R&D efforts across all of our therapeutic areas upon the retirement of Dr.Harald Reinhart at the end of June. This leadership transition allows for continued momentum and a strategic focus on our pipeline.
Recent Pipeline Highlights
Below are key product updates since our last earnings release:
Oncology Pipeline
- Niraparib (PARP): In
July 2024 ,Zai Lab announced that data of a Zai-supported study published in Cell provides new insights with potential to improve treatment of HRD-positive ovarian cancers, including through neoadjuvant monotherapy with niraparib and a combination of niraparib and ZL-1218, an investigational CCR8 antibody.
- Bemarituzumab (FGFR2b):
– In
– The enrollment is ongoing for the global Phase 3 FORTITUDE-102 study of bemarituzumab plus chemotherapy and nivolumab in first-line gastric cancer in mainland
- AUGTYRO™ (Repotrectinib) (ROS1/TRK):
– In
– In
- ZL-1310 (DLL3 ADC): The enrollment in
the United States andGreater China is ongoing for the global Phase 1 study in relapsed and refractory second-line+ small cell lung cancer (SCLC) who have progressed on or after platinum-based chemotherapy.
- ZL-1218 (CCR8): The enrollment in
the United States ,Europe , andGreater China is ongoing for the global Phase 1 study of ZL-1218 as a single agent and in combination with pembrolizumab in patients with advanced solid tumor malignancies.
Immunology, Neuroscience, and Infectious Disease Pipeline
- Efgartigimod (FcRn):
– In
– In
- XACDURO® (Sulbactam-Durlobactam or SUL-DUR): In
May 2024 , the NMPA approved the NDA for XACDURO for the treatment of adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.
- Xanomeline-Trospium (KarXT) (M1/M4-agonist): In
July 2024 ,Zai Lab joined the global Phase 3 ADEPT-2 study in Alzheimer’s disease with psychosis inGreater China .
- ZL-1102 (IL-17 Humabody®): In
May 2024 ,Zai Lab dosed the first patient in a global Phase 2 study evaluating the efficacy and safety of ZL-1102 for the treatment of chronic plaque psoriasis (CPP).
Anticipated Major Milestones in 2024 and the First Half of 2025
Potential Regulatory Submissions to the NMPA
- TTFields: Marketing Authorization Application (MAA) submission in second-line+ NSCLC following progression on or after platinum-based chemotherapy in the fourth quarter of 2024.
- Tisotumab Vedotin (Tissue Factor ADC): BLA submission in recurrent or metastatic cervical cancer following progression on or after chemotherapy.
- Repotrectinib (ROS1/TRK): supplementary NDA (sNDA) submission in NTRK+ solid tumors.
- Xanomeline-Trospium (KarXT) (M1/M4-agonist): NDA submission in schizophrenia.
Efgartigimod (FcRn)
Zai Lab to join the registrational study of efgartigimod SC given by prefilled syringe in Thyroid Eye Disease (TED) inGreater China in the fourth quarter of 2024.
- argenx to provide topline data from the Phase 2/3 ALKIVIA study evaluating efgartigimod across three myositis subsets (immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and dermatomyositis (DM)) in the fourth quarter of 2024.
Zai Lab to join the Phase 3 portion of this study in the fourth quarter of 2024.
Zai Lab to join the global registrational Phase 3 studies in seronegative gMG and ocular MG in early 2025, aiming to expand the label into broader MG populations.
Xanomeline-Trospium (KarXT) (M1/M4-agonist)
Zai Lab to complete patient enrollment of theChina registrational bridging study in schizophrenia, with topline data expected by the end of 2024.
- BMS to report data from the EMERGENT-4 and EMERGENT-5 trials evaluating the long-term safety for treatment of schizophrenia in the second half of 2024.
TTFields
- Novocure to provide a topline data readout from the Phase 3 PANOVA-3 clinical trial in locally advanced pancreatic cancer in the fourth quarter of 2024. We are participating in the study in
Greater China .
ZL-1310 (DLL3 ADC)
- Potential dose escalation data from the global Phase 1 study in relapsed and refractory second-line+ SCLC at the end of 2024 or early 2025.
ZL-1218 (CCR8)
- Present the preliminary clinical PK and PD analysis of the global Phase 1 study in solid tumors at 2024
European Society for Medical Oncology (ESMO) inSeptember 2024 .
Conference Call and Webcast Information
Details are as follows:
Registration Link: https://register.vevent.com/register/BIaccafead4b094cf191720bf5d03048c6
All participants must use the link provided above to complete the online registration process in advance of the conference call. Dial-in details will be in the confirmation email which the participant will receive upon registering.
A replay will be available shortly after the call and can be accessed by visiting the Company's website.
About
For additional information about
Non-GAAP Measures
In addition to results presented in accordance with GAAP, we disclose growth rates that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into
Zai Lab Forward-Looking Statements
This press release contains forward-looking statements relating to our strategy and plans; potential of and expectations for our business and pipeline programs; our goals, objectives, and priorities and our expectations under our growth strategy (including our expectations regarding our commercial products and launches, clinical stage products, revenue growth, profitability, and cash flow); clinical development programs and related clinical trials; clinical trial data, data readouts, and presentations; risks and uncertainties associated with drug development and commercialization; regulatory discussions, submissions, filings, and approvals and the timing thereof; the potential benefits, safety, and efficacy of our products and product candidates and those of our collaboration partners; the anticipated benefits and potential of investments, collaborations, and business development activities; our future financial and operating results; and financial guidance, including with respect to our planned sources and uses of cash and our expected path to profitability. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would,” and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products; (2) our ability to obtain funding for our operations and business initiatives; (3) the results of our clinical and pre-clinical development of our product candidates; (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates; (5) risks related to doing business in
Our
Unaudited Condensed Consolidated Balance Sheets
(in thousands of
|
|
|
|
|
|
||
|
Assets |
|
|
|
|
||
|
Current assets |
|
|
|
|
||
|
Cash and cash equivalents |
|
630,048 |
|
|
790,151 |
|
|
Restricted cash, current |
|
100,000 |
|
|
— |
|
|
Short-term investments |
|
— |
|
|
16,300 |
|
|
Accounts receivable (net of allowance for credit losses of |
|
69,635 |
|
|
59,199 |
|
|
Notes receivable |
|
8,102 |
|
|
6,134 |
|
|
Inventories, net |
|
41,846 |
|
|
44,827 |
|
|
Prepayments and other current assets |
|
20,292 |
|
|
22,995 |
|
|
Total current assets |
|
869,923 |
|
|
939,606 |
|
|
Restricted cash, non-current |
|
1,116 |
|
|
1,113 |
|
|
Long term investments |
|
4,073 |
|
|
9,220 |
|
|
Prepayments for equipment |
|
46 |
|
|
111 |
|
|
Property and equipment, net |
|
50,613 |
|
|
53,734 |
|
|
Operating lease right-of-use assets |
|
13,102 |
|
|
14,844 |
|
|
Land use rights, net |
|
2,991 |
|
|
3,069 |
|
|
Intangible assets, net |
|
44,063 |
|
|
13,389 |
|
|
Long-term deposits |
|
1,441 |
|
|
1,209 |
|
|
Total assets |
|
987,368 |
|
|
1,036,295 |
|
|
Liabilities and shareholders’ equity |
|
|
|
|
||
|
Current liabilities |
|
|
|
|
||
|
Accounts payable |
|
127,344 |
|
|
112,991 |
|
|
Current operating lease liabilities |
|
7,581 |
|
|
7,104 |
|
|
Short-term debt |
|
70,298 |
|
|
— |
|
|
Other current liabilities |
|
46,495 |
|
|
82,972 |
|
|
Total current liabilities |
|
251,718 |
|
|
203,067 |
|
|
Deferred income |
|
25,343 |
|
|
28,738 |
|
|
Non-current operating lease liabilities |
|
5,803 |
|
|
8,047 |
|
|
Other non-current liabilities |
|
325 |
|
|
325 |
|
|
Total liabilities |
|
283,189 |
|
|
240,177 |
|
|
Commitments and contingencies |
|
|
|
|
||
|
Shareholders’ equity |
|
|
|
|
||
|
Ordinary shares (par value of |
|
6 |
|
|
6 |
|
|
Additional paid-in capital |
|
3,011,964 |
|
|
2,975,302 |
|
|
Accumulated deficit |
|
(2,329,728 |
) |
|
(2,195,980 |
) |
|
Accumulated other comprehensive income |
|
42,773 |
|
|
37,626 |
|
|
Treasury Stock (at cost, 4,912,200 shares as of both |
|
(20,836 |
) |
|
(20,836 |
) |
|
Total shareholders’ equity |
|
704,179 |
|
|
796,118 |
|
|
Total liabilities and shareholders’ equity |
|
987,368 |
|
|
1,036,295 |
|
Unaudited Condensed Consolidated Statements of Operations
(in thousands of $, except for number of shares and per share data)
|
|
|
Three Months Ended |
|
Six Months Ended |
||||||||
|
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
|
Revenues |
|
|
|
|
|
|
|
|
||||
|
Product revenue, net |
|
100,106 |
|
|
68,864 |
|
|
187,255 |
|
|
131,661 |
|
|
Collaboration revenue |
|
398 |
|
|
— |
|
|
398 |
|
|
— |
|
|
Total revenues |
|
100,504 |
|
|
68,864 |
|
|
187,653 |
|
|
131,661 |
|
|
Expenses |
|
|
|
|
|
|
|
|
||||
|
Cost of product revenue |
|
(35,148 |
) |
|
(23,763 |
) |
|
(68,767 |
) |
|
(45,100 |
) |
|
Cost of collaboration revenue |
|
(85 |
) |
|
— |
|
|
(85 |
) |
|
— |
|
|
Research and development |
|
(61,625 |
) |
|
(76,682 |
) |
|
(116,270 |
) |
|
(125,153 |
) |
|
Selling, general, and administrative |
|
(79,710 |
) |
|
(67,920 |
) |
|
(148,904 |
) |
|
(130,430 |
) |
|
Gain on sale of intellectual property |
|
— |
|
|
10,000 |
|
|
— |
|
|
10,000 |
|
|
Loss from operations |
|
(76,064 |
) |
|
(89,501 |
) |
|
(146,373 |
) |
|
(159,022 |
) |
|
Interest income |
|
9,330 |
|
|
10,090 |
|
|
18,988 |
|
|
20,321 |
|
|
Interest expense |
|
(492 |
) |
|
— |
|
|
(605 |
) |
|
— |
|
|
Foreign currency losses |
|
(4,108 |
) |
|
(40,079 |
) |
|
(6,176 |
) |
|
(31,167 |
) |
|
Other (expenses) income, net |
|
(8,943 |
) |
|
(1,405 |
) |
|
418 |
|
|
(171 |
) |
|
Loss before income tax |
|
(80,277 |
) |
|
(120,895 |
) |
|
(133,748 |
) |
|
(170,039 |
) |
|
Income tax expense |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
Net loss |
|
(80,277 |
) |
|
(120,895 |
) |
|
(133,748 |
) |
|
(170,039 |
) |
|
Loss per share - basic and diluted |
|
(0.08 |
) |
|
(0.13 |
) |
|
(0.14 |
) |
|
(0.18 |
) |
|
Weighted-average shares used in calculating net loss per ordinary share - basic and diluted |
|
975,937,790 |
|
|
964,817,310 |
|
|
974,541,780 |
|
|
963,140,360 |
|
Unaudited Condensed Consolidated Statements of Comprehensive Loss
(in thousands of $)
|
|
|
Three Months Ended |
|
Six Months Ended |
||||||||
|
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
|
Net loss |
|
(80,277 |
) |
|
(120,895 |
) |
|
(133,748 |
) |
|
(170,039 |
) |
|
Other comprehensive income, net of tax of nil: |
|
|
|
|
|
|
|
|
||||
|
Foreign currency translation adjustments |
|
3,605 |
|
|
34,908 |
|
|
5,147 |
|
|
26,495 |
|
|
Comprehensive loss |
|
(76,672 |
) |
|
(85,987 |
) |
|
(128,601 |
) |
|
(143,544 |
) |
Non-GAAP Measures
(in thousands of $)
|
|
|
Three Months Ended |
|
Year over Year % |
|
Six Months Ended |
|
Year over Year % |
||||||||||||||||
|
|
|
2024 |
|
|
2023 |
|
|
As reported |
|
At CER* |
|
2024 |
|
|
2023 |
|
|
As reported |
|
At CER* |
||||
|
Product revenue, net |
|
100,106 |
|
|
68,864 |
|
|
45 |
% |
|
47 |
% |
|
187,255 |
|
|
131,661 |
|
|
42 |
% |
|
45 |
% |
|
Loss from operations |
|
(76,064 |
) |
|
(89,501 |
) |
|
(15 |
)% |
|
(15 |
)% |
|
(146,373 |
) |
|
(159,022 |
) |
|
(8 |
)% |
|
(8 |
)% |
* The growth rates at CER were calculated assuming the same foreign currency exchange rates were in effect for the current and prior year periods.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806076148/en/
For more information:
Investor Relations:
+1 (917) 886-6929 / +86 136 8257 6943
christine.chiou1@zailaboratory.com / lina.zhang@zailaboratory.com
Media:
+1 (415) 317-7255 / +86 185 0015 5011
shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com
Source: